Tag Archives: pfizer

Erectile dysfunction, Mens Health, Sexual health, Uncategorized, Viagra

New Viagra Skin Patch

In 1998, Viagra was the first and only oral pill to be approved by the FDA to treat impotence, also known as erectile dysfunction.

Scientists have been trying for many years to develop new ways to get a drug like Viagra into the blood stream without going via the stomach to reduce the risk of side effects.

But a team at King Abdulaziz University in Jeddah, Saudi Arabia, along with scientists at Cairo University have made a breakthrough  and developed the first stick on patch to treat erectile dysfunction (ED), containing the same active ingredient in Viagra – Sildenafil Citrate.

The patch can take effect within minutes and still be effective beyond 10 hours, compared to Viagra which takes 30-60 minutes to take effect and is only effective for up to 4 hours.

Men will no longer suffer from the side effects which are caused by ingesting the little blue pill such as indigestion, migraines and headaches.

The new skin plaster, which can be worn on the upper arm or abdomen, has been tested on rats and the results were promising.

There are currently no indications as to when (or if) it will be approved for use in the UK.

If it does get approved, it will only be available as a Prescription Only Medication (POM) like Viagra, Cialis and Levitra.

So, until the patch actually becomes available, if you, or someone you love, have been diagnosed with ED, then perhaps prescription medication (such as Cialis, Levitra, or Viagra) would be an appropriate treatment.

For more information about ED or prescription medication to treat it, or for a free private online consultation (with a UK GMC-registered doctor) about treatment for the condition, please CLICK HERE.

To read more about the new Viagra patch, please CLICK HERE.

Drugs, General

Could Sildenafil Increase Skin Cancer Risk?

Sildenafil, the active ingredient in Viagra, was originally developed to treat heart conditions, but during original trials it was found to be more effective at treating erectile dysfunction (also known as impotence).sildenafil

But now, scientists have warned that the drug could increase the risk of melanoma – the deadliest form of skin cancer.

Researchers at the University of Tübingen in Germany have discovered that Sildenafil can encourage tumors to grow more rapidly.

A recent study found that Sildenafil can stimulate skin cancer growth.

Sildenafil has a stimulating effect on the messenger molecule cyclic guanosine monophosphate (cGMP), which promotes the growth of existing malignant melanomas.

The scientist came to this conclusion through animal experiments and human cell cultures.

Cells normally contain an enzyme called phosphodiesterase type 5 (PDE5), that ensures the newly-formed cGMP is continuously broken down.

But, Sildenafil belongs to a group of medicines called phosphodiesterase type 5 (PDE 5) inhibitors.

Study author Professor Robert Feil said: ‘Taking sildenafil basically disables this brake.’

Consequently, the melanoma begins to grow more aggressively.

However, the study noted that there is no reason for men to stop taking PDE5 inhibitors to treat erectile dysfunction.

The researchers also have to take into account that the possibility that a higher incidence of skin cancer may be due to lifestyles, including sunbathing on holiday.

Professor Feil warned: ‘Ultimately, we should all be thinking about reducing our risk of skin cancer and cutting our exposure time to the sun, as well as using effective UV protection.’

Sildenafil is marketed as Viagra and was approved by FDA (The Food and Drug Administration) on 27th March 1988. Pfizer’s patent on Sildenafil expired on 21 June 2013.

If you are concerned that Sildenafil (Viagra) could increase the risk of skin cancer then there is other alternative prescription only  medication for erectile dysfunction such as Cialis and Levitra.

For further information about Sildenafil (Viagra) and other erectile dysfunction medication, please go to www.ukmeds4u.com.

To read the full article, please click here.